Ashlesha Vishweshwar Sangmuly
About Ashlesha Vishweshwar Sangmuly
Ashlesha Vishweshwar Sangmuly has 11 years in corporate governance. Holds Director role. Currently with 2 companies, including Ashvimon Pharma Private Limited and Auxano Surgytech Private Limited. Formerly with 1 company, such as Vivatest Research And Development Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Ashvimon Pharma Private Limited
U24299PN2019PTC183953
|
Director | 06 May 2019 | 2019 | Active |
Auxano Surgytech Private Limited
U33113PN2017PTC169297
|
Director | 08 Mar 2017 | 2017 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Vivatest Research And Development Private Limited
U74999MH2014PTC259700
|
Additional Director | 12 Dec 2014 | 2014 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Ashlesha Vishweshwar Sangmuly
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ashlesha Vishweshwar Sangmuly
Ashlesha Vishweshwar Sangmuly has 11 years in corporate governance. Holds Director role. Currently with 2 companies, including Ashvimon Pharma Private Limited and Auxano Surgytech Private Limited. Formerly with 1 company, such as Vivatest Research And Development Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Ashlesha Vishweshwar Sangmuly is associated with 2 companies as Director.
Ashlesha Vishweshwar Sangmuly has expertise in General Business, Technology.
Ashlesha Vishweshwar Sangmuly has 11 years in corporate governance.